Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Graphite Bio, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 8-K Appointed a new director
07/20/2023 8-K Quarterly results
06/06/2023 ARS Form ARS - Annual Report to Security Holders:
06/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/27/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/20/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/20/2023 10-K Annual Report for the period ended December 31, 2022
03/20/2023 8-K Quarterly results
03/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/22/2023 8-K Quarterly results
02/14/2023 SC 13G/A Samsara BioCapital, L.P. reports a 14.6% stake in Graphite Bio, Inc.
01/09/2023 SC 13G/A EcoR1 Capital, LLC reports a 14.7% stake in Graphite Bio, Inc.
01/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel for Sickle Cell Disease"
12/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
11/18/2022 SC 13G EcoR1 Capital, LLC reports a 9.8% stake in Graphite Bio, Inc.
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
Docs: "Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023 Two abstracts accepted for 64th ASH Annual Meeting and Exposition in December"
11/03/2022 8-K Quarterly results
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
07/29/2022 EFFECT Form EFFECT - Notice of Effectiveness:
07/21/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
07/13/2022 8-K/A Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting"
06/23/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/12/2022 8-K Quarterly results
04/29/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy